In patients with homologous recombination deficiency (HRD) or somatic/germline BRCA1/2 (Breast Cancer 1/ Breast Cancer 2) mutations, maintenance treatment after response to platinum-based chemotherapy consists of Poly-ADP-Ribose-Polymerase-inhibitors (PARPi) olaparib in combination with bevacizumab [2]. This evidence concerns the gene BRCA1 and breast carcinoma.